Jennifer Kranz1, Stefanie Schmidt, Cordula Lebert, Laila Schneidewind, Guido Schmiemann, Florian Wagenlehner. 1. Department of Urology and Pediatric Urology, St. Antonius Hospital Eschweiler, Academic Teaching Hospital of RWTH Aachen, Eschweiler; UroEvidence@Deutsche Gesellschaft für Urologie, Berlin; Pharmacy, Nuremberg Hospitals; Hematology/Oncology, Department of Internal Medicine C, Faculty of Medicine, University of Greifswald; Department of Care Research, Institute for Public Health and Nursing Care Research, University of Bremen; Department of Urology, Pediatric Urology and Andrology, University Hospital of Gießen and Marburg Ltd., Justus-Liebig University Gießen.
Abstract
BACKGROUND: Uncomplicated bacterial community-acquired urinary tract infection is among the more common infections in outpatient practice. The resistance level of pathogens has risen markedly. This S3 guideline contains recommendations based on current evidence for the rational use of anti - microbial agents and for the prevention of inappropriate use of certain classes of antibiotics and thus of the resulting drug resistance. The prevention of recurrent urinary tract infection is considered in this guideline for the first time. METHODS: The guideline was updated under the aegis of the German Urological Society (Deutsche Gesellschaft für Urologie). A systematic literature search (period: 2008-2015) concerning the diagnosis, treatment, and prevention of uncomplicated urinary tract infections was carried out in the Cochrane Library, MEDLINE, and Embase databases. Randomized, controlled trials and systemic reviews were included. Relevant guidelines were identified in a guideline synopsis. RESULTS: Symptom-oriented diagnostic evaluation is highly valued. For the treatment of cystitis, fosfomycin-trometamol, nitrofurantoin, nitroxolin, pivmecillinam and trimethoprim are all equally recommended. Fluorquinolones and cephalosporins are not recommended. Uncomplicated pyelonephritis with a mild to moderate clinical course ought to be treated with oral cefpodoxime, ceftibuten, ciprofloxacin, or levofloxacin. For acute, uncomplicated cystitis, with mild to moderate symptoms, symptomatic treatment alone may be considered instead of antibiotics after discussion of the options with the patient. Mainly non-antibiotic measures are recommended for prophylaxis against recurrent urinary tract infection. CONCLUSION: Physicians who treat uncomplicated urinary tract infections should familiarize themselves with the newly revised guideline's recommendations on the selection and dosage of antibiotic treatment so that they can responsibly evaluate and plan antibiotic treatment for their affected patients.
BACKGROUND: Uncomplicated bacterial community-acquired urinary tract infection is among the more common infections in outpatient practice. The resistance level of pathogens has risen markedly. This S3 guideline contains recommendations based on current evidence for the rational use of anti - microbial agents and for the prevention of inappropriate use of certain classes of antibiotics and thus of the resulting drug resistance. The prevention of recurrent urinary tract infection is considered in this guideline for the first time. METHODS: The guideline was updated under the aegis of the German Urological Society (Deutsche Gesellschaft für Urologie). A systematic literature search (period: 2008-2015) concerning the diagnosis, treatment, and prevention of uncomplicated urinary tract infections was carried out in the Cochrane Library, MEDLINE, and Embase databases. Randomized, controlled trials and systemic reviews were included. Relevant guidelines were identified in a guideline synopsis. RESULTS: Symptom-oriented diagnostic evaluation is highly valued. For the treatment of cystitis, fosfomycin-trometamol, nitrofurantoin, nitroxolin, pivmecillinam and trimethoprim are all equally recommended. Fluorquinolones and cephalosporins are not recommended. Uncomplicated pyelonephritis with a mild to moderate clinical course ought to be treated with oral cefpodoxime, ceftibuten, ciprofloxacin, or levofloxacin. For acute, uncomplicated cystitis, with mild to moderate symptoms, symptomatic treatment alone may be considered instead of antibiotics after discussion of the options with the patient. Mainly non-antibiotic measures are recommended for prophylaxis against recurrent urinary tract infection. CONCLUSION: Physicians who treat uncomplicated urinary tract infections should familiarize themselves with the newly revised guideline's recommendations on the selection and dosage of antibiotic treatment so that they can responsibly evaluate and plan antibiotic treatment for their affected patients.
Authors: Brenda M Kazemier; Fiona N Koningstein; Caroline Schneeberger; Alewijn Ott; Patrick M Bossuyt; Esteriek de Miranda; Tatjana E Vogelvang; Corine J M Verhoeven; Josje Langenveld; Mallory Woiski; Martijn A Oudijk; Jeanine E M van der Ven; Manita T W Vlegels; Petra N Kuiper; Nicolette Feiertag; Eva Pajkrt; Christianne J M de Groot; Ben W J Mol; Suzanne E Geerlings Journal: Lancet Infect Dis Date: 2015-08-05 Impact factor: 25.071
Authors: Daniel Drozdov; Stefanie Schwarz; Alexander Kutz; Eva Grolimund; Anna Christina Rast; Deborah Steiner; Katharina Regez; Ursula Schild; Merih Guglielmetti; Antoinette Conca; Barbara Reutlinger; Cornelia Ottiger; Florian Buchkremer; Sebastian Haubitz; Claudine Blum; Andreas Huber; Ulrich Buergi; Philipp Schuetz; Andreas Bock; Christoph Andreas Fux; Beat Mueller; Werner Christian Albrich Journal: BMC Med Date: 2015-05-01 Impact factor: 8.775
Authors: Laila Schneidewind; Fabian P Stangl; Desiree L Dräger; Florian M E Wagenlehner; Oliver W Hakenberg; Jennifer Kranz Journal: Urologie Date: 2022-07-13
Authors: Andreas Plate; Andreas Kronenberg; Martin Risch; Yolanda Mueller; Stefania Di Gangi; Thomas Rosemann; Oliver Senn Journal: BMC Fam Pract Date: 2020-07-01 Impact factor: 2.497
Authors: Matthew R Carey; Valerie M Vaughn; Jason Mann; Whitney Townsend; Vineet Chopra; Payal K Patel Journal: J Gen Intern Med Date: 2020-04-08 Impact factor: 5.128
Authors: Ria Benko; Maria Matuz; Zoltan Juhasz; Julia Bognar; Reka Bordas; Gyongyver Soos; Edit Hajdu; Zoltan Peto Journal: Front Pharmacol Date: 2019-12-19 Impact factor: 5.810